Skip to main content
PLOS Genetics logoLink to PLOS Genetics
. 2021 Jul 6;17(7):e1009556. doi: 10.1371/journal.pgen.1009556

CRISPR/Cas9 modified An. gambiae carrying kdr mutation L1014F functionally validate its contribution in insecticide resistance and combined effect with metabolic enzymes

Linda Grigoraki 1,*, Ruth Cowlishaw 1, Tony Nolan 1, Martin Donnelly 1, Gareth Lycett 1, Hilary Ranson 1,*
Editor: Subba Reddy Palli2
PMCID: PMC8284791  PMID: 34228718

Abstract

Insecticide resistance in Anopheles mosquitoes is a major obstacle in maintaining the momentum in reducing the malaria burden; mitigating strategies require improved understanding of the underlying mechanisms. Mutations in the target site of insecticides (the voltage gated sodium channel for the most widely used pyrethroid class) and over-expression of detoxification enzymes are commonly reported, but their relative contribution to phenotypic resistance remain poorly understood. Here we present a genome editing pipeline to introduce single nucleotide polymorphisms in An. gambiae which we have used to study the effect of the classical kdr mutation L1014F (L995F based on An. gambiae numbering), one of the most widely distributed resistance alleles. Introduction of 1014F in an otherwise fully susceptible genetic background increased levels of resistance to all tested pyrethroids and DDT ranging from 9.9-fold for permethrin to >24-fold for DDT. The introduction of the 1014F allele was sufficient to reduce mortality of mosquitoes after exposure to deltamethrin treated bednets, even as the only resistance mechanism present. When 1014F was combined with over-expression of glutathione transferase Gste2, resistance to permethrin increased further demonstrating the critical combined effect between target site resistance and detoxification enzymes in vivo. We also show that mosquitoes carrying the 1014F allele in homozygosity showed fitness disadvantages including increased mortality at the larval stage and a reduction in fecundity and adult longevity, which can have consequences for the strength of selection that will apply to this allele in the field.

Author summary

Escalation of pyrethroid resistance in Anopheles mosquitoes threatens to reduce the effectiveness of our most important tools in malaria control. Studying the mechanisms underlying insecticide resistance is critical to design mitigation strategies. Here, using genome modified mosquitoes, we functionally characterize the most prevalent mutation in resistant mosquitoes, showing that it confers substantial levels of resistance to all tested pyrethroids and undermines the performance of pyrethroid-treated nets. Furthermore, we show that combining this mutation with elevated levels of a detoxification enzyme further increases resistance. The pipeline we have developed provides a robust approach to quantifying the contribution of different combinations of resistance mechanisms to the overall phenotype, providing the missing link between resistance monitoring and predictions of resistance impact.

Introduction

The widespread use of insecticides in indoor residual spraying and insecticide-treated bednets (ITNs) has been a critical driver in the reduction of malaria cases in the last decades [1]. These tools have been so effective because they reduce the density and the lifespan of mosquitoes and thus their ability to transmit the Plasmodium parasite. However, gains in malaria control are now stalling [2] and this has been attributed, at least partially, to increasing levels of insecticide resistance in Anopheles vectors [3]. As malaria vector control relies on a limited range of chemicals and new insecticides need years to be developed and approved, it is critical to preserve the effectiveness of available compounds. To do that we need to understand the mechanisms by which insects have evolved resistance and design mitigation strategies.

The molecular basis of insecticide resistance is complex with multiple mechanisms co-existing. The two most widely reported adaptations include mutations at the target site that reduce the insecticide’s binding affinity and increased production of detoxification enzymes, like P450s, esterases and GSTs (glutathione transferases) that inactivate the insecticide molecules and enhance their excretion [4]. More recently additional mechanisms have been described, including cuticular modifications that reduce the insecticide’s penetration rate [5] and insecticide sequestration from chemosensory proteins [6]. Although in many cases the association of these mechanisms with insecticide resistance is clear, we are still lacking critical knowledge about the effect size of each mechanism and importantly the combined effect of different mechanisms. It has been hypothesized that the synergistic effect of different mechanisms is what leads to operational control failure, [7] but there is little data to support this prediction. This knowledge gap reduces our ability to interpret the results of the various molecular diagnostics that have been developed to screen for the presence of insecticide resistance mechanisms in field populations, simply because the predictive value of the markers used is unclear [8].

Insecticide resistance mechanisms often carry fitness costs. Therefore, removal of the insecticide, as a selection pressure, is predicted to reduce the frequency of resistance alleles in the population. This is the basis of insecticide resistance management strategies that alternate the use of chemistries with different mode of action. However, not all resistance alleles pose high fitness costs, in which case they can persist in populations, and in some cases additional mutations with a compensating role can be selected. Thus, it is important to evaluate the cost of each documented resistance mechanism and make evidence-based decisions on insecticide alternations. A key bottleneck is the ability to compare the effect of specific mutations on defined genetic backgrounds. To date, several studies have documented fitness costs for target-site resistance mutations, but these studies are rarely performed on genetically related strains, which complicates the interpretation of results and often the establishment of a direct link [9].

In this study we examine the contribution to insecticide resistance and the associated fitness costs for mutation L1014F on the An. gambiae voltage gated sodium channel (VGSC). Mutation L1014F (or L995F using the Anopheles gambiae codon numbering), also known as classical kdr (knock-down resistance), was among the first mechanisms associated with resistance to the organochlorine DDT and to pyrethroids [10]. Pyrethroids are a particularly important insecticide class as they are used in all ITNs, even the newer nets that combine two chemistries, due to their low mammalian toxicity and fast mode of action. Therefore, it is commonplace to genotype for this mutation as an adjunct to resistance prevalence bioassays. Several studies have tried to measure the effect size of L1014F in pyrethroid resistance, either by associating its presence with survival to insecticide exposure [1113], by introgressing the mutation in an insecticide susceptible strain [14,15] or by genetically modifying Drosophila melanogaster [16]. The outcomes of these studies vary, with some reporting a low effect size, while others a moderate to high [17]. However, in all cases the results could be influenced by confounding factors arising either from differences in the genetic background of the mosquito strains compared, or due to the use of a model organism that might not reflect the exact response in mosquitoes.

Here, we have used CRISPR/Cas9 to introduce the L1014F mutation in an An. gambiae insecticide susceptible strain providing the opportunity to investigate the direct effect of this mutation on several traits with the minimum possible confounding effects. This is the first time to our knowledge a mosquito strain has been genome edited to functionally validate a single mutation and we provide an experimental pipeline for studies wishing to do the same. We also report the generation of a transgenic An. gambiae line in which we have combined the L1014F mutation with over-expression of the detoxification enzyme Gste2, which permits functional validation of the combined effect of target site and detoxification enzymes in vivo.

Results

Generation of a genome modified An. gambiae line bearing the L1014F VGSC mutation in an insecticide susceptible background

Embryos of the insecticide susceptible Kisumu strain were injected with a CRISPR/Donor plasmid mix (Materials and Methods) and 32 larvae (G0) were obtained with RFP (the Red Fluorescent Protein-marker present on the CRISPR plasmid) expression predominantly in their anal papillae, that indicated these fluorescent individuals had actively transcribed plasmids delivered. A subset of each female’s G1 progeny was screened for the presence of genetically modified alleles using a LNA diagnostic assay [18]. A positive transformation event was found in progeny of one G0 female at a frequency of 18% (Table A in S1 Text) and verified through sequencing. Sequencing of the vgsc region in the transformed line also revealed, based on the presence in the donor construct of silent SNPs (Fig A in S1 Text), that DNA resection during CRISPR reached from one side at least 199bp and from the other side less than 158bp. Thus, even if a gRNA target is not available at or close (within 20 bp) to the mutation site, which is the preferred option, it is still possible to recover transformants with gRNAs targeting a region further away. A summary of the strategy used to generate the Kisumu-F/F line (which is para1014F/F homozygous) is illustrated in Fig 1.

Fig 1. CRISPR/Cas9 strategy for the generation of Kisumu-F/F line.

Fig 1

A) Injection of Kisumu eggs (In this case N = 338) with an appropriate CRISPR (Cas9+gRNA)/Donor mix resulted in CRISPR induced homology directed repair (HDR) and conversion of the wild type allele to the mutant L1014F allele. B) Only individuals with transient expression of RFP in their anal papillae (In this case 32 out of 128 larvae that hatched), which is expressed from the CRISPR plasmid, were pooled in sex-specific founder cages, and backcrossed to Kisumu individuals. C) Females (G0 and Kisumu females mated with G0 males) were left to lay individually (in this case 24 females: 5 G0 females and 19 Kisumu Females laid eggs), then a subset of their progeny (max 30%) was sacrificed and screened in pools of 2 larvae each with a LNA assay for identification of positive transformants (G1). Α single positive G1 pool was identified. The remaining siblings in the pool were reared until the pupal stage and transferred to individual tubes to emerge. Post-eclosion the pupal cases were used to screen for the presence of the mutant allele. Individuals that carried the mutant allele were used to establish the line.

Genome modified mosquitoes carrying the L1014F mutation show increased levels of resistance to all tested pyrethroids and DDT

The extent of the resistance phenotype conferred by mutation L1014F was initially tested using WHO discriminating dose assays. The concentration of insecticides in these assays is fixed at twice the lethal concentration that kills 99% of the susceptible mosquitoes after 1h of exposure and mortality of less than 90% is the threshold to define resistance [19]. Based on these criteria L1014F confers WHO defined resistance to the pyrethroids, permethrin and α -cypermethrin only in homozygosity (recessive character) (Fig 2B and 2D), while it confers resistance to DDT in heterozygosity (dominant character) (Fig 2A). A reduction in mortality for Kisumu-F/F individuals against deltamethrin, was observed although not statistically significant (Fig 2C). The percentage of mosquitoes being knocked down immediately after the 1h exposure period was also recorded for each insecticide (S1 Data and Fig B in S1 Text). In all cases except deltamethrin, there is significant inhibition of knock down after 1hr exposure in F/F mosquitoes, but in F/L genotypes a knockdown resistance phenotype was only observed against DDT. There was no significant difference between 1hr knock down and 24 hr mortality for any insecticide or genotype (S1 Data and Fig B in S1 Text). As expected, no resistance was observed against the carbamate insecticide bendiocarb (S1 Data) that targets the acetylcholinesterase and not the VGSC.

Fig 2. Measurement of sensitivity to insecticides using WHO tube bioassays.

Fig 2

2–5-day old females were exposed to standard WHO discriminating doses for 1h and mortality recorded 24h later. Error bars represent the SD (At least 3 replicates of 20 mosquitoes each were used per strain). The dotted line marks the WHO 90% mortality threshold for defining resistance. Welch’s t test with P < 0.05 significance cutoff. **P < 0.01; ***P < 0.001; ****P< 0.0001.

To further quantify the level of resistance conferred by L1014F to the insecticides we performed time response assays and estimated the time required to obtain 50% mortality (LT50) for each of the three genotypes (Table 1). Kisumu-F/F exhibited the highest predicted Resistance Ratio (RR50) against DDT (> 24.5-fold) although accurate determination of the LT50 for DDT was not possible in mutant homozygotes, as mortality of Kisumu-F/F was less than 23% after 9 hours of exposure to DDT, which was the latest time point measured. The RR50 for α-cypermethrin was 19.7-fold, for deltamethrin 14.6-fold and for permethrin 9.9-fold. Lower RR50 were observed for the heterozygote (Kisumu-L/F) mosquitoes in all cases (Table 1), thus L1014F under the exposure conditions used has a semidominant effect on resistance.

Table 1. Time response bioassay results.

Insecticide Strain LT50 (St. Error) Upper and Lower Limits RR50
Deltamethrin Kisumu-F/F 31.5min (3.3) 38.2–24.8 14.6 (19.3–10.0)
Kisumu-L/F 9.1 min (1.4) 12.0–6.2 4.2 (5.9–2.5)
Kisumu-L/L 2.1 min (0.25) 2.6–1.6
Permethrin Kisumu-F/F 160.5 (11.0) 182.5–138.4 9.9 (13.2–6.6)
Kisumu-L/F 24.3 (2.5) 29.5–19.1 1.5 (2.0–0.95)
Kisumu-L/L 16 (2.4) 20.9–11.2
a-cypermethrin Kisumu-F/F 77.5 (3.7) 84.9–70.1 19.7 (23.6–15.8)
Kisumu-L/F 12.9 (1.2) 15.4–10.3 3.2 (4.1–2.4)
Kisumu-L/L 3.9 (0.33) 4.5–3.2
DDT Kisumu-F/F >540min >24.5
Kisumu-L/F ~211.6 (10.8) 189.8–233.3 9.6 (8.2–10.9)
Kisumu-L/L 22.0 (1.3) 24.6–19.4

The LT50 (time required to obtain 50% mortality) values are given for each strain. Resistant Ratios (LT50 resistant strain/ LT50 control strain) are given in comparison to Kisumu-L/L. Upper and Lower limits represent the 95% fiducial limits of the LT50. For each time point at least 3 replicates of 20 female mosquitoes 2–5 day old were used per strain. Raw data provided in S1 Data.

L1014F reduces mortality of mosquitoes after contact with deltamethrin treated ITNs

To assess the impact of the L1014F mutation on ITN effectiveness, we performed standard WHO cone bioassays exposing females of the Kisumu-F/F strain and the Kisumu-L/L strain to PermaNet 2.0 (impregnated with deltamethrin) and control untreated nets, for 3min. 100% mortality was recorded for the Kisumu-L/L females 24h after exposure to PermaNet2.0, while the mean mortality rate for the Kisumu-F/F strain was significantly less at ≈65% (P = 0.0003, Welch’s test)(Fig 3). No mortality was recorded in the control untreated nets.

Fig 3. Cone Bioassay with PermaNet 2.0.

Fig 3

The percentage mortality 24h after exposure is depicted for the Kisumu-F/F and Kisumu strains. Nine replicates of five females each were tested. Error bars show SD. Welch’s t test with P < 0.05 significance cutoff. **P < 0.01; ***P < 0.001.

Pre-exposure to PBO increases mortality of the Kisumu-F/F strain to deltamethrin

Piperonyl butoxide (PBO) significantly enhances the efficacy of pyrethroids by inhibiting the function of P450 detoxification enzymes and/or by acting as an adjuvant, enhancing insecticide uptake [20]. Here we used the Kisumu-F/F strain to demonstrate that PBO pre-exposure significantly reduces deltamethrin resistance, even in the absence of metabolic resistance. In the absence of PBO, 25min exposure to the standard WHO discriminating dose of deltamethrin resulted in a mean mortality of 13.7±7.9%, while 1h pre-exposure to PBO resulted in a significant increase in mortality (mean mortality of 84.7±0.86%) (Fig 4).

Fig 4. Mortality to Deltamethrin with and without pre-exposure to PBO.

Fig 4

The percentage mortality is shown 24h after: A) 1h exposure to 4% PBO, B) 25min exposure to 0.05% deltamethrin and C) 1h exposure to 4% PBO immediately followed by 25min exposure to 0.05% deltamethrin. Four replicates of 15–21 females, 2–5 days old each were used. Error bars show SD. Welch’s t test with P < 0.05 significance cutoff. **P < 0.01; ***P < 0.001; ****P < 0.0001.

The L1014F mutation carries fitness costs

We investigated the effect of mutation L1014F on several life history traits. In terms of growth, a significantly lower percentage of Kisumu-F/F larvae (mean of 75%) reached the pupae stage compared to wild type Kisumu-L/L (mean of 91%; P<0.0001) (Fig 5A). In addition, the fecundity of Kisumu-F/F females was significantly reduced with 35.7% of females not producing eggs, after one blood meal, compared to 10.7% for the Kisumu-L/L females (P = 0.003) (Fig 5B). In contrast the fertility (number of eggs laid) was not significantly different between the two genotypes (mean number of eggs laid by Kisumu-F/F was 72 (±24 SD) compared to 83 (± 37 SD) for Kisumu-L/L) (Fig 5C), nor the number of larvae that hatched (mean number of larvae hatched for each Kisumu-F/F female 54 (±26 SD) compared to 55 (±30 SD) for Kisumu-L/L (P >0.05) (Fig 5D). Finally, the lifespan of female Kisumu-F/F was significantly reduced (median age decreased from 24 to 21 days) compared to Kisumu-L/L females (P = 0.02) (Fig 5E).

Fig 5. Evaluating the pleiotropic effects of L1014F on different life history traits.

Fig 5

A) Difference in the mean percentage of L1 larvae reaching the pupae stage is shown for the Kisumu-F/F (75%) and Kisumu-L/L (91%) strains. 10 replicates were tested in total, 7 replicates of 70 larvae each and 3 replicates of 200 larvae each. Error bars represent the SD. Unpaired t-test, P <0.0001. B) Pie charts showing the difference in fecundity (percentage of females that oviposited at least one egg vs females that did not). The total number of females tested per strain was 56. Fisher’s exact test, P = 0.0031. C)The mean number of eggs laid per female was not statistically significant between the Kisumu-F/F (N = 72) and Kisumu (N = 83) strains. Error bars represent the SD. Mann-Whitney (P = 0.062). D) the mean number of larvae that hatched per female is shown for the two strains. No significant difference was observed. Mann-Whitney-test (P = 0.91). E) Longevity of female mosquitoes under standard lab conditions. Thirty females in total were tested per strain. Mantel-Cox test (P = 0.02),*P ≤ 0.05; **P ≤ 0.01; ***P ≤ 0.001; ****P ≤ 0.0001.

Over-expression of Gste2 increases resistance of mosquitoes carrying mutation L1014F

To investigate the combined effect of target site mutations and detoxification enzymes we used a previously generated [21] transgenic strain ubiquitously over-expressing the detoxification enzyme Gste2, and through genetic crosses with the Kisumu-F/F strain generated a line: (Kisumu-F/F)/Gste2 (para1014F/F; Ubi-A10GAL4:UAS-GSTe2) carrying both resistance mechanisms in an otherwise susceptible genetic background. The mean mortality of individuals from the (Kisumu-F/F)/Gste2 line was 17.2% after 160min exposure to permethrin treated WHO papers, compared to a mean mortality of 65.5% for the Kisumu-F/F line and 100% for the Gste2 overexpressing line (Fig 6), showing the combined effect of these two mechanisms.

Fig 6. Multi-tissue over-expression of Gste2 further reduces mortality of mosquitoes from the Kisumu-F/F strain to permethrin.

Fig 6

WHO tube bioassay representing mortality rate after 160min of exposure. The Gste2 line (Ubi-A10GAL4:UAS-GSTe2) showed close to 100% mortality after 1h exposure, as shown by Adolfi et al [21] and 100% mortality after 160min. Three replicates of 15–20 female mosquitoes each were used for the Kisumu-F/F and (Kisumu-F/F)/Gste2 lines and two replicates of 15 female mosquitoes for the Gste2 line. Error bars represent SD. Welch’s t test with P = 0.03.

Discussion

In vivo functional validation is critical in establishing the importance of candidate mechanisms, alone and in combination, in phenotypic insecticide resistance. Here we have used CRISPR/Cas9 to introduce the VGSC mutation L1014F, which is widespread in insecticide resistant An. gambiae populations in Africa, in an insecticide susceptible genetic background. Ordinarily genome modification strategies use a dominant fluorescent marker to identify rare transformants. However, studying the role of single nucleotide polymorphisms precludes the introduction of additional sequences, as these could confound the interpretation of results. In this study we show that the CRISPR/Cas9 strategy we followed achieves transformation rates high enough to recover transformants without the aid of a dominant marker gene and thus can be used in An. gambiae to study the role of single nucleotide polymorphisms. Its applicability to other mosquito species will depend on the rates of homology directed repair, which can be lower than we achieved in An. gambiae [22]. The use of CRISPR/Cas9 to study the effect of target site mutations in insecticide resistance has been predominantly performed using the model organism Drosophila melanogaster [16, 2325] and in one agricultural pest [26], thus our study reports, to the best of our knowledge, the first time this approach being used in a major insect vector of human disease pathogens. Several target-site resistance mutations have been described in these insects whose effect size needs to be clarified, but which could be assessed following the approach described here; these include mutations in acetylcholinesterase, the target of organophosphate and carbamate insecticides, the GABA-gated chloride channel that is associated with dieldrin resistance [27] and the chitin synthase that is associated with resistance to diflubenzuron and other benzoylurea insecticides inhibiting this enzyme [25,28].

Introduction of L1014F in the Kisumu susceptible background increased insecticide resistance against all pyrethroid insecticides tested and DDT, with resistance levels ranging from 9.9-fold for permethrin to >24.5-fold for DDT in quantitative assays. The very high levels of resistance to DDT, observed even for heterozygous individuals, suggests that L1014F was originally selected by the widespread use of DDT and retained in the populations after introduction of pyrethroids, by conferring lower, but still substantial levels of resistance. Permethrin and deltamethrin resistance observed in Kisumu-F/F is very similar to the levels of insensitivity L1014F confers to Ae. aegypti VGSCs expressed in the Xenopus oocyte system (8-fold for permethrin and 14-fold for deltamethrin) [29]. In that system insensitivity is calculated based on the percentage of channels whose activity is being modified by pyrethroids. In the case of deltamethrin although the quantitative bioassay showed a 14-fold increase in resistance, similar to the 13-fold reported for transgenic Drosophila carrying the equivalent mutation [16], the WHO bioassay involving 1h exposure to a discriminating dose did not define Kisumu-F/F mosquitoes as resistant (mortality <90%). Thus, the WHO discriminating dose for deltamethrin seems to have a higher threshold than the doses recommended for other pyrethroids, making it difficult to compare resistance between compounds using the standard 1h time point. Moreover, the WHO diagnostic assay failed to detect resistance in heterozygotes to any of the pyrethroids, whereas heterozygous mutants were clearly resistant to DDT with this test. Quantitative bioassays however showed resistance of heterozygotes for all tested pyrethroids ranging from 1.5-fold for permethrin to 4.2-fold for deltamethrin. This is a clear illustration of the limitation that standard WHO bioassays face in identifying populations where 1014F is increasing in frequency, if only pyrethroid sensitivity is assayed, given that even a population with 100% heterozygotes could be classified as susceptible to the three main pyrethroid insecticides. Our WHO and quantitative bioassay data also demonstrate that characterizing resistance as a recessive or dominant trait depends on the type of assay and conditions used. For example, the 1014F allele is dominant for DDT resistance using the standard WHO bioassay, but recessive based on the quantitative analysis.

We also showed that the 1014F allele when in homozygosity is sufficient to induce reduced mortality after mosquitoes are exposed to commercial, deltamethrin treated ITNs. We recorded a 67.5% mortality in the standard WHO cone bioassay for Kisumu-F/F. This is higher than the 26% mortality that was previously reported [14] for the kdr-Kisumu line, which was generated by introgressing the L1014F mutation from a resistant field strain into Kisumu [15]. Although introgression substantially dilutes the resistance genetic background, it is impossible, even with multiple rounds of crossing, to achieve the resolution that allows one to look at the effects of a mutation in isolation. This is particularly relevant for centromeric loci located in low recombination regions, such as the vgsc [30]. In addition, whole genome sequencing data from the Anopheles gambiae 1000 Genomes Project, have shown a high genetic variation in the vgsc gene itself. Twenty non-synonymous substitutions were identified, thirteen of which were found to occur almost exclusively on haplotypes carrying the L1014F resistance allele and may enhance or compensate for the L1014F resistance phenotype [31]. Thus, the higher levels of resistance obtained for the introgressed line could be related to the presence of additional unscreened mutations in the vgsc allele originating from the parental resistant population or the presence of other genes that are carried over during introgression.

The P450 inhibitor PBO is commonly used to estimate the contribution of P450 metabolism to resistance phenotypes. Here we showed that pre-exposure to PBO increased mortality of the Kis-L1014F strain after deltamethrin exposure. This enhancement in deltamethrin efficacy, even in the absence of metabolic resistance, could be either mediated through the inhibition of the endogenous levels of P450s, that might still contribute to resistance when in combination with the L1014F mutation, or by enhancing the penetration, and thus bioavailability, of the insecticide through the cuticle [20]. Either way, this result suggests that demonstration of elevated P450 levels is not a necessary pre-requisite for use of PBO containing products to mitigate against resistance, as has previously been recommended.

Combining mutation L1014F with over-expression of the detoxification enzyme Gste2 resulted in increased levels of resistance to permethrin. Transgenic mosquitoes over-expressing Gste2 (allele carrying the I114T variant associated with DDT resistance [32]), as the only resistance mechanism have previously been shown to be resistant to DDT and the organophosphate insecticide fenitrothion, but not to permethrin or deltamethrin [21]. However metabolic assays with recombinant An. funestus Gste2 have shown its ability to directly metabolise DDT and permethrin in vitro [33]. Thus, the An. gambiae Gste2 is either a poor permethrin metaboliser that needs the presence of target-site resistance to show a phenotypic effect or it mainly metabolises secondary metabolites of permethrin that can also have toxic effects. We had intended to test the combined effect of Gste2 and L1014F in DDT resistance, but the insensitivity of the Kisumu-F/F line even after long exposure times and high doses of DDT in topical applications, precluded detection of any further increase in resistance with the addition of Gste2. However, the permethrin data support the hypothesis [16] that the different mechanisms can interact in An. gambiae, and that their combined effect ultimately shapes the resistance phenotype in mosquitoes. Although the mechanisms of this interaction have not been elucidated yet, there are several hypotheses as described in [16]. The kdr mutation, by reducing the binding affinity of the insecticide, could provide more time for detoxification enzymes to act and avoid saturation. Alternatively, the detoxification enzymes could reduce the number of parental insecticide molecules reaching the nervous system or generate less-toxic metabolites with an even further reduced binding affinity to the mutated VGSC.

In addition to the impact on insecticide resistance we showed that L1014F has pleiotropic effects on fitness related traits. It has long been hypothesized that L1014F carries fitness costs [34], but providing a direct association had been complicated by the comparison of populations with different genetic backgrounds [35]. Although we cannot rule out the possibility of CRIPSR induced off-targets or haplotype-specific effects in the Kisumu-F/F line, the comparison we perform involves the least possible confounding genetic effects. We show that significantly fewer individuals from the Kisumu-F/F strain are able to develop from early instar larvae to pupae. This could also explain, at least partially, the lower than expected number of homozygous individuals observed in the process of establishing the Kisumu-F/F line. In addition, a significantly lower number of females from the Kisumu-F/F line oviposited. Although we did not measure insemination rates, this may be related to the reported association of VGSC mutations with reduced male mating success [36], and warrants further investigation in future. A reduced lifespan was also observed for Kisumu-F/F females, which could be even more pronounced under field conditions. However, it should be noted that fitness costs related to the L1014F mutation could be ameliorated by compensatory mechanisms in wild populations. For example, several additional non-synonymous mutations are found on the vgsc gene in linkage with L1014F, which is consistent with them either conferring additional resistance or compensating for the deleterious effects of L1014F [31,37, 38], and can be examined by further mutagenesis of the Kisumu-F/F line generated herein.

Conclusions

Understanding the mechanisms of insecticide resistance and their phenotypic contribution can provide predictive value for molecular diagnostic markers to be used as resistance prevalence monitoring tools and assist in resistance control program decision making. This work reports the functional validation of mutation L1014F, which is widely used as a marker of pyrethroid resistance in malaria vectors, but without a clear understanding of how precisely it affects the performance of insecticide-based vector control tools. We show that L1014F even in isolation, provides substantial levels of insecticide resistance that impact the performance of ITNs, but critically resistance levels are further increased when combined with the over-expression of a metabolic enzyme, the Gste2. This highlights the importance of interpreting molecular diagnostics carefully, considering the synergistic or additive effects of the different mechanisms. Further work is needed to investigate the complex interactions of the different insecticide resistance mechanisms and the different mutations on the vgsc gene; the ability, demonstrated here, to introduce precise and defined mutations in any combination, on any given haplotype offers a powerful tool to finally dissect these interactions. This in turn will greatly increase the predictive value of multi-locus diagnostic panels to detect and track the emergence of insecticide resistance, with the potential to be transformative for insecticide resistance management programs.

Materials and methods

Mosquito rearing

All mosquitoes were maintained under standard insectary conditions, at 26°C ± 2°C and 70% relative humidity ± 10% under L12:D12 hour light:dark photoperiod. All stages of larvae were fed on ground fish food (Tetramin tropical flakes, Tetra, Blacksburg, VA, USA) and adults were provided with 10% sucrose solution ad libitum.

Genome modification strategy

CRISPR/Cas9 coupled with homology directed repair (HDR) was used to introduce the L1014F VGSC mutation in the insecticide susceptible An. gambiae strain, Kisumu.

Generation of Cas9 plasmid

The p174 plasmid generated in [39], carrying: a human-codon-optimized Cas9 under the control of the germline specific zpg (zero population growth) promoter, a 3xP3::RFP marker and a U6::gRNA spacer cloning cassette was used. p174 was digested with BsaI and specific gRNA spacers (listed in Table B in S1 Text) targeting the vgsc locus near the L1014 codon, were introduced under the control of the U6 polIII promoter. This was done through Golden Gate cloning of annealed oligos with compatible overhangs (Table B in S1 Text). Identification of multiple gRNA target sites and assessment of off-targets was performed using the ZiFiT (http://zifit.partners.org/) and ChopChop (https://chopchop.rc.fas.harvard.edu) websites. As described in Fig A in S1 Text, the guide RNA that proved successful in generating mutants was gRNA 2.

Generation of Donor for HDR

A 1,600 bp region of the Voltage Gated Sodium Channel (vgsc, AGAP004707-RA) gene having the 1014 codon in the middle (homology arms extending 800 bp either direction) was synthesized de novo by Genescript in a puc19 vector, including the A→T transversion that generates the L1014F mutation (codon alteration TTA→TTT) and other synonymous SNPs in the gRNA target sites to avoid cleavage of the vector by Cas9 (Fig A in S1 Text).

Mosquito embryo injections and identification of G1 transformants

Freshly laid eggs of the Kisumu strain were microinjected with a mix of the Cas9 and donor plasmids (300ng/ul each). In order to enrich for those individuals injected with appreciable quantities of the Cas9 and donor plasmid mix, surviving G0 larvae expressing RFP (present on the Cas9 plasmid as a 3xP3:RFP) transiently in the anal papillae were reared separately and backcrossed with the Kisumu strain in sex-specific cages. Females of both crosses were put in individually egg-laying tubes and a subset of their progeny (G1) was used to screen for positive transformants. DNA was extracted from G1 larvae in pools of two by grinding them in 30ul of STE buffer (0.1M NaCl, 10mM Tris-HCl pH 8, 1mM EDTA pH 8), followed by a 25min incubation at 95°C. 2ul of DNA extract was used in a previously established LNA based diagnostic assay for the L1014F mutation [18].

Establishment of Kisumu-F/F line

Where genome-modified alleles were identified in progeny of a G1 female, siblings were left to develop and added in individual emergence tubes once they reached the pupae stage. The day after adult emergence the pupae case left behind was lysed in 10 ul of STE buffer at 95 oC for 25min. 2ul were used to identify heterozygotes with the LNA based diagnostic assay. Heterozygotes were backcrossed once more with the Kisumu strain in sex-specific cages to obtain higher numbers of individuals carrying the mutant allele (G2). Heterozygote G2 individuals were intercrossed to obtain homozygote G3 individuals. A sufficiently high number of homozygotes able to establish the strain were obtained after several generations of intercrossing, as the number of homozygous mutants was lower than expected, possibly due to the observed fitness costs. The locus of the genome edited strain was verified by sequencing the PCR product of the L1014externalF1 and L1014externalR1 primers (Table B in S1 Text) at Genwiz.

Establishment of (Kisumu-F/F)/ Gste2 line

Males of the Gste2 line generated and described in Adolfi et al.,2019 [21], expressing the Gste2 metabolic enzyme (allele including the I114T substitution, associated with DDT resistance [32]) under an endogenous polyubiquitin promoter:Gal4 fusion (A10) and marked with 3xP3 driven yellow fluorescent protein, were crossed with females of the Kisumu-F/F line. G1 male progeny, heterozygotes for Ubi-A10GAL4:UAS-Gste2 and L1014F were crossed with females of the Kisumu-F/F strain. Once progeny of this cross reached the pupae stage, they were first screened under a fluorescent microscope for a YFP signal. YFP positive individuals were left to emerge in individual tubes. The pupae case left behind was used to extract DNA and screen through the L1014F LNA assay, as described in the previous paragraph, for homozygotes. Individuals from the (Kisumu-F/F)/Gste2 line used in toxicity bioassays were 1014F/F, but a mix of heterozygotes (one copy) and homozygotes (two copies) for Ubi-A10GAL4:UAS-Gste2.

Assessment of insecticide susceptibility

WHO tube bioassays

WHO tube bioassays were performed as described in [40] using insecticide impregnated papers of standard discriminating doses: 0.75% permethrin, 0.05% deltamethrin, 0.1% bendiocarb, 4% DDT and 4% PBO (obtained from Universiti Sains Malaysia). To determine the LT50 (exposure time resulting in 50% mortality) we varied the exposure time (S1 Data). Knock down was scored immediately after exposure and mortality after a 24hour recovery time. At least 3 replicates of 20 females (2–5 days old) each were performed for each time point. A control tube with no insecticide was included in each test for each strain. LT50, Resistance Ratio and associated statistical parameters were calculated from log-logistic 2 parameter dose response models using the drc package from [41] and the drm(), compParm(), ED() and EDcomp() functions in R statistical software (version 3.4.3).

Cone bioassays

Cone bioassays were performed as described in [42] using PermaNet 2.0 nets (obtained directly by Vestergaard). Νine replicates of five female mosquitoes, 2–5 days old were tested using at least three randomly selected pieces of the nets (control and treated). Mosquitoes were exposed for 3min and then transferred to recovery cups. Mortality was recorded 24h later.

Life history traits

Development to pupae

Seven replicate trays (23cm x 34cm x 7cm) containing 70 larvae each and three replicate trays containing 200 larvae each (for testing possible differences in pupation rate depending on larvae densities) were set up for the Kisumu and Kisumu-F/F strains. Larvae of the two strains were treated in the same way, fed equal amount of TetraMin fish food (using standard size spatulas) and reared under standard insectary conditions. The number of individuals reaching the pupae stage was recorded every day. A two-tailed unpaired student’s t-test was used (GraphPad Prism 9.0.0) to compare pupation rates.

Fecundity and fertility

Three replicate mating buckets each containing 20 females and 30 males were set up for the Kisumu and Kisumu-F/F homozygous strains. Mosquitoes were fed five days later with our standard ‘blood’ supply (50,50 mix of human research red cells and plasma, NHS blood and transplant service) using a Hemotek membrane feeding system. Those that did not feed were removed from the experiment. Two days post blood feeding females were placed in individual laying cups containing 20 ml of water. Females were aspirated out of the cups two days later and oviposited eggs were counted under a stereoscope. The number of females that laid (at least one egg) and did not lay were recorded and analyzed using a Fisher’s exact test (GraphPad Prism 9.0.0). Larvae that hatched were counted four days later to include any with a delayed hatching. Statistical comparison of egg and larvae counts was done using a Mann-Whitney U test (GraphPad Prism 9.0.0).

Adult longevity

Thirty females from each strain, were transferred in pools of five in six replicate cups and fed ad libitum with 10% (w/v) sugar solution. Mortality was recorded every day and dead mosquitoes removed. Longevity was assessed using GraphPad Prism 9.0.0 using a Mantel-Cox test.

Supporting information

S1 Text. CRISPR/Cas9 strategy for generating Kisumu-F/F.

Fig A: Strategy for the construction of the CRISPR/Cas9 donor plasmid. The nucleotide sequence of the central part (600bp) of the An. gambiae vgsc (Gene ID: AGAP004707) fragment (1,600bp in total) used to construct the CRISPR/Cas9 donor plasmid for HDR is depicted. Light orange areas correspond to exons 18 and 19. Position 2,422,652 (based on the AgamP3 reference sequence, chromosome arm 2L) where an A>T transversion generates the TTA―›TTT codon alteration creating mutation L1014F is marked with an asterisk. Underlined sequences correspond to the selected CRRISPR/Cas9 targets (gRNAs 1,2,3 and 4). Green areas mark the PAM (-NGG) triplets for each gRNA in the target sequence. Red letters show the SNPs introduced in the donor sequence. These include silent mutations in the gRNA target site to avoid cleavage of the donor plasmid from Cas9 and the A>T transversion creating mutation L1014F. Letters below red letters show the original sequence. Sequencing of the region in individuals from the Kisumu-F/F strain revealed that silent mutations introduced in the target sequences of gRNA’s 2,3 and 4 were retained while those of gRNA 1 were not. Fig B: Comparison of knock-down and mortality. The percentage of mosquitoes being knocked-down (immobile or unable to stand or take off) immediately after exposure to standard WHO assays (1h exposure time) was recorded, as well as the mortality 24h later based on standard WHO criteria (2). Error bars represent the SD (At least 3 replicates of 20, 2–5 day old female mosquitoes each were used per strain). Table A: Summary of screening G1 progeny to identify positive transformants. Table B: Primers used.

(DOCX)

S1 Data. Raw data for toxicity bioassays and fitness cost experiments.

(XLSX)

Acknowledgments

We would like to thank Beth Poulton (LSTM) for assistance with the R code used to analyze the time response assays and her help in rearing the Gste2 transgenic colony. We would also like to thank Fraser Colman (LSTM) for long term maintenance and provision of the Gste2 transgenic line, Sara Elg (LSTM) for assistance with maintenance of the Kisumu lines and Manuela Bernardi (LSTM) for providing the mosquito illustrations used in Fig 1.

Data Availability

All relevant data are within the manuscript and its Supporting Information files.

Funding Statement

This study was funded by the Wellcome Trust (https://wellcome.org/), Sir Henry Wellcome Postdoctoral fellowship, Grant reference number: [215894/Z/19/Z] to LG. For the purpose of open access, the author has applied a CC-BY public copyright license to any author accepted manuscript version arising from this submission The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

References

  • 1.Bhatt S, Weiss DJ, Cameron E, Bisanzio D, Mappin B, Dalrymple U, et al. The effect of malaria control on Plasmodium falciparum in Africa between 2000 and 2015. Nature. 2015;526(7572):207–11. doi: 10.1038/nature15535 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.WHO. World Malaria Report 2018 (World Health Organization, Geneva, Switzerland, 2018). 2018. [Google Scholar]
  • 3.Churcher TS, Lissenden N, Griffin JT, Worrall E, Ranson H. The impact of pyrethroid resistance on the efficacy and effectiveness of bednets for malaria control in Africa. Elife. 2016;5. doi: 10.7554/eLife.16090 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Hemingway J, Hawkes NJ, McCarroll L, Ranson H. The molecular basis of insecticide resistance in mosquitoes. Insect Biochem Mol Biol. 2004;34(7):653–65. doi: 10.1016/j.ibmb.2004.03.018 [DOI] [PubMed] [Google Scholar]
  • 5.Balabanidou V, Grigoraki L, Vontas J. Insect cuticle: a critical determinant of insecticide resistance. Curr Opin Insect Sci. 2018;27:68–74. doi: 10.1016/j.cois.2018.03.001 [DOI] [PubMed] [Google Scholar]
  • 6.Ingham VA, Anthousi A, Douris V, Harding NJ, Lycett G, Morris M, et al. A sensory appendage protein protects malaria vectors from pyrethroids. Nature. 2020;577(7790):376–80. doi: 10.1038/s41586-019-1864-1 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Melissa C H, Jeffrey G S. A review of the interactions between multiple insecticide resistance loci. Pesticide Biochemistry and Physiology. 2010;97(2). [Google Scholar]
  • 8.Weetman D, Donnelly MJ. Evolution of insecticide resistance diagnostics in malaria vectors. Trans R Soc Trop Med Hyg. 2015;109(5):291–3. doi: 10.1093/trstmh/trv017 [DOI] [PubMed] [Google Scholar]
  • 9.Ffrench-Constant RH, Bass C. Does resistance really carry a fitness cost? Curr Opin Insect Sci. 2017;21:39–46. doi: 10.1016/j.cois.2017.04.011 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Martinez-Torres D, Chandre F, Williamson MS, Darriet F, Berge JB, Devonshire AL, et al. Molecular characterization of pyrethroid knockdown resistance (kdr) in the major malaria vector Anopheles gambiae s.s. Insect Mol Biol. 1998;7(2):179–84. doi: 10.1046/j.1365-2583.1998.72062.x [DOI] [PubMed] [Google Scholar]
  • 11.Kwiatkowska RM, Platt N, Poupardin R, Irving H, Dabire RK, Mitchell S, et al. Dissecting the mechanisms responsible for the multiple insecticide resistance phenotype in Anopheles gambiae s.s., M form, from Vallee du Kou, Burkina Faso. Gene. 2013;519(1):98–106. doi: 10.1016/j.gene.2013.01.036 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Edi CV, Koudou BG, Jones CM, Weetman D, Ranson H. Multiple-insecticide resistance in Anopheles gambiae mosquitoes, Southern Cote d’Ivoire. Emerg Infect Dis. 2012;18(9):1508–11. doi: 10.3201/eid1809.120262 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Reimer L, Fondjo E, Patchoke S, Diallo B, Lee Y, Ng A, et al. Relationship between kdr mutation and resistance to pyrethroid and DDT insecticides in natural populations of Anopheles gambiae. J Med Entomol. 2008;45(2):260–6. doi: 10.1603/0022-2585(2008)45[260:rbkmar]2.0.co;2 [DOI] [PubMed] [Google Scholar]
  • 14.Allossogbe M, Gnanguenon V, Yovogan B, Akinro B, Anagonou R, Agossa F, et al. WHO cone bio-assays of classical and new-generation long-lasting insecticidal nets call for innovative insecticides targeting the knock-down resistance mechanism in Benin. Malar J. 2017;16(1):77. doi: 10.1186/s12936-017-1727-x [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Alout H, Ndam NT, Sandeu MM, Djegbe I, Chandre F, Dabire RK, et al. Insecticide resistance alleles affect vector competence of Anopheles gambiae s.s. for Plasmodium falciparum field isolates. PLoS One. 2013;8(5):e63849. doi: 10.1371/journal.pone.0063849 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Samantsidis GR, Panteleri R, Denecke S, Kounadi S, Christou I, Nauen R, et al. ’What I cannot create, I do not understand’: functionally validated synergism of metabolic and target site insecticide resistance. Proc Biol Sci. 2020;287(1927):20200838. doi: 10.1098/rspb.2020.0838 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Donnelly MJ, Isaacs AT, Weetman D. Identification, Validation, and Application of Molecular Diagnostics for Insecticide Resistance in Malaria Vectors. Trends Parasitol. 2016;32(3):197–206. doi: 10.1016/j.pt.2015.12.001 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Lynd A, Oruni A, Van’t Hof AE, Morgan JC, Naego LB, Pipini D, et al. Insecticide resistance in Anopheles gambiae from the northern Democratic Republic of Congo, with extreme knockdown resistance (kdr) mutation frequencies revealed by a new diagnostic assay. Malar J. 2018;17(1):412. doi: 10.1186/s12936-018-2561-5 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Organization WH. Test Procedures for Insecticide Resistance Monitoring in Malaria Vector Mosquitoes (World Health Organization, Geneva, Switzerland, ed. 2, 2016). [Google Scholar]
  • 20.Bingham G, Strode C, Tran L, Khoa PT, Jamet HP. Can piperonyl butoxide enhance the efficacy of pyrethroids against pyrethroid-resistant Aedes aegypti? Trop Med Int Health. 2011;16(4):492–500. doi: 10.1111/j.1365-3156.2010.02717.x [DOI] [PubMed] [Google Scholar]
  • 21.Adolfi A, Poulton B, Anthousi A, Macilwee S, Ranson H, Lycett GJ. Functional genetic validation of key genes conferring insecticide resistance in the major African malaria vector, Anopheles gambiae. Proc Natl Acad Sci U S A. 2019;116(51):25764–72. doi: 10.1073/pnas.1914633116 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Li M, Bui M, Yang T, Bowman CS, White BJ, Akbari OS. Germline Cas9 expression yields highly efficient genome engineering in a major worldwide disease vector, Aedes aegypti. Proc Natl Acad Sci U S A. 2017;114(49):E10540–E9. doi: 10.1073/pnas.1711538114 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Xue W, Mermans C, Papapostolou KM, Lamprousi M, Christou IK, Inak E, et al. Untangling a Gordian knot: the role of a GluCl3 I321T mutation in abamectin resistance in Tetranychus urticae. Pest Manag Sci. 2020. doi: 10.1002/ps.6215 [DOI] [PubMed] [Google Scholar]
  • 24.Douris V, Denecke S, Van Leeuwen T, Bass C, Nauen R, Vontas J. Using CRISPR/Cas9 genome modification to understand the genetic basis of insecticide resistance: Drosophila and beyond. Pestic Biochem Physiol. 2020;167:104595. doi: 10.1016/j.pestbp.2020.104595 [DOI] [PubMed] [Google Scholar]
  • 25.Grigoraki L, Puggioli A, Mavridis K, Douris V, Montanari M, Bellini R, et al. Striking diflubenzuron resistance in Culex pipiens, the prime vector of West Nile Virus (vol 7, 11699, 2017). Sci Rep-Uk. 2018;8. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Wang X, Ma Y, Wang F, Yang Y, Wu S, Wu Y. Disruption of nicotinic acetylcholine receptor alpha6 mediated by CRISPR/Cas9 confers resistance to spinosyns in Plutella xylostella. Pest Manag Sci. 2020;76(5):1618–25. doi: 10.1002/ps.5689 [DOI] [PubMed] [Google Scholar]
  • 27.Liu N. Insecticide resistance in mosquitoes: impact, mechanisms, and research directions. Annu Rev Entomol. 2015;60:537–59. doi: 10.1146/annurev-ento-010814-020828 [DOI] [PubMed] [Google Scholar]
  • 28.Douris V, Steinbach D, Panteleri R, Livadaras I, Pickett JA, Van Leeuwen T, et al. Resistance mutation conserved between insects and mites unravels the benzoylurea insecticide mode of action on chitin biosynthesis. Proc Natl Acad Sci U S A. 2016;113(51):14692–7. doi: 10.1073/pnas.1618258113 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Wang L, Nomura Y, Du Y, Liu N, Zhorov BS, Dong K. A mutation in the intracellular loop III/IV of mosquito sodium channel synergizes the effect of mutations in helix IIS6 on pyrethroid resistance. Mol Pharmacol. 2015;87(3):421–9. doi: 10.1124/mol.114.094730 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Clarkson CS, Weetman D, Essandoh J, Yawson AE, Maslen G, Manske M, et al. Adaptive introgression between Anopheles sibling species eliminates a major genomic island but not reproductive isolation. Nat Commun. 2014;5:4248. doi: 10.1038/ncomms5248 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Clarkson CS, Miles A, Harding NJ, Weetman D, Kwiatkowski D, Donnelly M, et al. The genetic architecture of target-site resistance to pyrethroid insecticides in the African malaria vectors Anopheles gambiae and Anopheles coluzzii. bioRxiv. 2018. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Mitchell SN, Rigden DJ, Dowd AJ, Lu F, Wilding CS, Weetman D, et al. Metabolic and target-site mechanisms combine to confer strong DDT resistance in Anopheles gambiae. PLoS One. 2014;9(3):e92662. doi: 10.1371/journal.pone.0092662 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Riveron JM, Yunta C, Ibrahim SS, Djouaka R, Irving H, Menze BD, et al. A single mutation in the GSTe2 gene allows tracking of metabolically based insecticide resistance in a major malaria vector. Genome Biol. 2014;15(2):R27. doi: 10.1186/gb-2014-15-2-r27 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Lynd A, Weetman D, Barbosa S, Egyir Yawson A, Mitchell S, Pinto J, et al. Field, genetic, and modeling approaches show strong positive selection acting upon an insecticide resistance mutation in Anopheles gambiae s.s. Mol Biol Evol. 2010;27(5):1117–25. doi: 10.1093/molbev/msq002 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Nkahe DL, Kopya E, Djiappi-Tchamen B, Toussile W, Sonhafouo-Chiana N, Kekeunou S, et al. Fitness cost of insecticide resistance on the life-traits of a Anopheles coluzzii population from the city of Yaounde, Cameroon. Wellcome Open Res. 2020;5:171. doi: 10.12688/wellcomeopenres.16039.2 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.Rigby LM, Johnson BJ, Rasic G, Peatey CL, Hugo LE, Beebe NW, et al. The presence of knockdown resistance mutations reduces male mating competitiveness in the major arbovirus vector, Aedes aegypti. PLoS Negl Trop Dis. 2021;15(2):e0009121. doi: 10.1371/journal.pntd.0009121 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.Lucas ER, Rockett KA, Lynd A, Essandoh J, Grisales N, Kemei B, et al. A high throughput multi-locus insecticide resistance marker panel for tracking resistance emergence and spread in Anopheles gambiae. Sci Rep. 2019;9(1):13335. doi: 10.1038/s41598-019-49892-6 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.Jones CM, Liyanapathirana M, Agossa FR, Weetman D, Ranson H, Donnelly MJ, et al. Footprints of positive selection associated with a mutation (N1575Y) in the voltage-gated sodium channel of Anopheles gambiae. Proc Natl Acad Sci U S A. 2012;109(17):6614–9. doi: 10.1073/pnas.1201475109 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39.Hammond A, Karlsson X, Morianou I, Kyrou K, Beaghton A, Gribble M, et al. Regulating the expression of gene drives is key to increasing their invasive potential and the mitigation of resistance. PLoS Genet. 2021;17(1):e1009321. doi: 10.1371/journal.pgen.1009321 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 40.World Health Organization. Test Procedures for Insecticide Resistance Monitoring in Malaria Vector Mosquitoes. (World Health Organization, Geneva, Switzerland, ed 2, 2016). [Google Scholar]
  • 41.Ritz C, Baty F, Streibig JC, Gerhard D. Dose-Response Analysis Using R. PLoS One. 2015;10(12):e0146021. doi: 10.1371/journal.pone.0146021 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42.WHO. Guidelines for laboratory and field testing of long-lasting insecticidal mosquito nets.. Geneva: World Health Organization. 2013. [Google Scholar]

Decision Letter 0

Gregory P Copenhaver, Subba Reddy Palli

19 May 2021

Dear Dr Grigoraki,

Thank you very much for submitting your Research Article entitled 'CRISPR/Cas9 modified An. gambiae carrying kdr mutation L1014F functionally validate its contribution in insecticide resistance and interaction with metabolic enzymes.' to PLOS Genetics.

The manuscript was fully evaluated at the editorial level and by independent peer reviewers. The reviewers appreciated the attention to an important problem, but raised some concerns about the data presented in Figures 2&3. Based on the reviews, we will not be able to accept this version of the manuscript, but we would be willing to review a revised version. We cannot, of course, promise publication at that time.

Should you decide to revise the manuscript for further consideration here, your revisions should address the specific points made by each reviewer. We will also require a detailed list of your responses to the review comments and a description of the changes you have made in the manuscript.

If you decide to revise the manuscript for further consideration at PLOS Genetics, please aim to resubmit within the next 60 days, unless it will take extra time to address the concerns of the reviewers, in which case we would appreciate an expected resubmission date by email to plosgenetics@plos.org.

If present, accompanying reviewer attachments are included with this email; please notify the journal office if any appear to be missing. They will also be available for download from the link below. You can use this link to log into the system when you are ready to submit a revised version, having first consulted our Submission Checklist.

To enhance the reproducibility of your results, we recommend that you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. Additionally, PLOS ONE offers an option to publish peer-reviewed clinical study protocols. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols

Please be aware that our data availability policy requires that all numerical data underlying graphs or summary statistics are included with the submission, and you will need to provide this upon resubmission if not already present. In addition, we do not permit the inclusion of phrases such as "data not shown" or "unpublished results" in manuscripts. All points should be backed up by data provided with the submission.

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool.  PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at figures@plos.org.

PLOS has incorporated Similarity Check, powered by iThenticate, into its journal-wide submission system in order to screen submitted content for originality before publication. Each PLOS journal undertakes screening on a proportion of submitted articles. You will be contacted if needed following the screening process.

To resubmit, use the link below and 'Revise Submission' in the 'Submissions Needing Revision' folder.

[LINK]

We are sorry that we cannot be more positive about your manuscript at this stage. Please do not hesitate to contact us if you have any concerns or questions.

Yours sincerely,

Subba Reddy Palli, Ph.D.

Associate Editor

PLOS Genetics

Gregory P. Copenhaver

Editor-in-Chief

PLOS Genetics

Reviewer's Responses to Questions

Comments to the Authors:

Please note here if the review is uploaded as an attachment.

Reviewer #1: Acceptable for publication. Would have been nice to see LD50 data for the insecticides.

Reviewer #2: This manuscript describes the use of genome editing to introduce the pyrethroid resistance mutation L1014F into the VGSC of Anopheles gambiae. The impact of this on insecticide sensitivity and organismal fitness was assessed. Furthermore the interaction of this mutation with a metabolic mechanism, over-expression of glutathione transferase Gste2, was investigated.

The manuscript is very well written and the study innovative and important. The kdr mutation has been linked to resistance in An gambiae for more than two decades, however, the precise level of resistance conferred by this mechanism, in isolation or combination with other mechanisms, has remained unclear. This study emphatically demonstrates its importance in conferring resistance while also uncovering fitness costs associated with the mutations presence.

The results are thoroughly and carefully discussed and any potential limitations/confounding effects (i.e. from off-target effects of CRISPR-CAS) noted.

In summary I recommend this paper is accepted and the following typos corrected in production.

Line 192: change: Mutation L1014F carries fitness costs. To ‘The L1014F mutation carries fitness costs’.

Line 261: correct the grammer in the following sentence: The resistance observed for Kisumu-F/F against permethrin and deltamethrin are very similar to the levels of insensitivity mutation L1014F provides to Ae. aegypti VGSCs expressed in the in vitro Xenopus oocyte system (8-fold for permethrin and 14-fold for deltamethrin) (29).

Reviewer #3: In this paper, Grigoraki et al. generate an Anopheles gambiae transgenic line bearing a kdr mutation to further validate that kdr contributes to insecticide resistance. Using CRISPR/cas9 system, they edit the genome of a susceptible mosquito strain to introduce single nucleotide polymorphism (kdr mutation L1014F). They further test the mortality of this line using different insecticide compounds and confirm kdr mutation L1014F increases resistance to insecticides. Overexpression of gste2, a detoxification enzyme, in the kdr mutant line increase the resistance phenotype. Finally, they analyse the effect of the mutation on mosquito fitness. This paper is well written, clear and conclusions supported by the data. However, I do not think that this study reveals novel methods nor biological insights as it only confirms previous studies showing kdr is involved in resistance to insecticides and therefore, may be better suited for a more specific journal.

Minor comments

Why is there a lot of variation in F/F mosquitoes mortality after ITN exposure (Fig 3) with some mosquito groups showing a mortality above 90%, ie are susceptible?

The resistance to deltamethrin varies a lot as well (eg fig2 with 70-80% mortality vs fig4 with less than 20%). How can this be?

**********

Have all data underlying the figures and results presented in the manuscript been provided?

Large-scale datasets should be made available via a public repository as described in the PLOS Genetics data availability policy, and numerical data that underlies graphs or summary statistics should be provided in spreadsheet form as supporting information.

Reviewer #1: Yes

Reviewer #2: Yes

Reviewer #3: Yes

**********

PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: No

Reviewer #3: No

Decision Letter 1

Gregory P Copenhaver, Subba Reddy Palli

1 Jun 2021

Dear Dr Grigoraki,

Thank you very much for submitting your Research Article entitled 'CRISPR/Cas9 modified An. gambiae carrying kdr mutation L1014F functionally validate its contribution in insecticide resistance and combined effect with metabolic enzymes.' to PLOS Genetics.

The manuscript was fully evaluated at the editorial level and the editors ask that you address the comment from Reviewer 1 of the previous version and include the LD50 data for insecticides.

In addition we ask that you:

1) Provide a detailed list of your responses to the review comments and a description of the changes you have made in the manuscript.

2) Upload a Striking Image with a corresponding caption to accompany your manuscript if one is available (either a new image or an existing one from within your manuscript). If this image is judged to be suitable, it may be featured on our website. Images should ideally be high resolution, eye-catching, single panel square images. For examples, please browse our archive. If your image is from someone other than yourself, please ensure that the artist has read and agreed to the terms and conditions of the Creative Commons Attribution License. Note: we cannot publish copyrighted images.

We hope to receive your revised manuscript within the next 30 days. If you anticipate any delay in its return, we would ask you to let us know the expected resubmission date by email to plosgenetics@plos.org.

If present, accompanying reviewer attachments should be included with this email; please notify the journal office if any appear to be missing. They will also be available for download from the link below. You can use this link to log into the system when you are ready to submit a revised version, having first consulted our Submission Checklist.

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at figures@plos.org.

Please be aware that our data availability policy requires that all numerical data underlying graphs or summary statistics are included with the submission, and you will need to provide this upon resubmission if not already present. In addition, we do not permit the inclusion of phrases such as "data not shown" or "unpublished results" in manuscripts. All points should be backed up by data provided with the submission.

To enhance the reproducibility of your results, we recommend that you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. Additionally, PLOS ONE offers an option to publish peer-reviewed clinical study protocols. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols

Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice.

PLOS has incorporated Similarity Check, powered by iThenticate, into its journal-wide submission system in order to screen submitted content for originality before publication. Each PLOS journal undertakes screening on a proportion of submitted articles. You will be contacted if needed following the screening process.

To resubmit, you will need to go to the link below and 'Revise Submission' in the 'Submissions Needing Revision' folder.

[LINK]

Please let us know if you have any questions while making these revisions.

Yours sincerely,

Subba Reddy Palli, Ph.D.

Associate Editor

PLOS Genetics

Gregory P. Copenhaver

Editor-in-Chief

PLOS Genetics

Decision Letter 2

Gregory P Copenhaver, Subba Reddy Palli

8 Jun 2021

Dear Dr Grigoraki,

We are pleased to inform you that your manuscript entitled "CRISPR/Cas9 modified An. gambiae carrying kdr mutation L1014F functionally validate its contribution in insecticide resistance and combined effect with metabolic enzymes." has been editorially accepted for publication in PLOS Genetics. Congratulations!

Before your submission can be formally accepted and sent to production you will need to complete our formatting changes, which you will receive in a follow up email. Please be aware that it may take several days for you to receive this email; during this time no action is required by you. Please note: the accept date on your published article will reflect the date of this provisional acceptance, but your manuscript will not be scheduled for publication until the required changes have been made.

Once your paper is formally accepted, an uncorrected proof of your manuscript will be published online ahead of the final version, unless you’ve already opted out via the online submission form. If, for any reason, you do not want an earlier version of your manuscript published online or are unsure if you have already indicated as such, please let the journal staff know immediately at plosgenetics@plos.org.

In the meantime, please log into Editorial Manager at https://www.editorialmanager.com/pgenetics/, click the "Update My Information" link at the top of the page, and update your user information to ensure an efficient production and billing process. Note that PLOS requires an ORCID iD for all corresponding authors. Therefore, please ensure that you have an ORCID iD and that it is validated in Editorial Manager. To do this, go to ‘Update my Information’ (in the upper left-hand corner of the main menu), and click on the Fetch/Validate link next to the ORCID field.  This will take you to the ORCID site and allow you to create a new iD or authenticate a pre-existing iD in Editorial Manager.

If you have a press-related query, or would like to know about making your underlying data available (as you will be aware, this is required for publication), please see the end of this email. If your institution or institutions have a press office, please notify them about your upcoming article at this point, to enable them to help maximise its impact. Inform journal staff as soon as possible if you are preparing a press release for your article and need a publication date.

Thank you again for supporting open-access publishing; we are looking forward to publishing your work in PLOS Genetics!

Yours sincerely,

Subba Reddy Palli, Ph.D.

Associate Editor

PLOS Genetics

Gregory P. Copenhaver

Editor-in-Chief

PLOS Genetics

www.plosgenetics.org

Twitter: @PLOSGenetics

----------------------------------------------------

Comments from the reviewers (if applicable):

----------------------------------------------------

Data Deposition

If you have submitted a Research Article or Front Matter that has associated data that are not suitable for deposition in a subject-specific public repository (such as GenBank or ArrayExpress), one way to make that data available is to deposit it in the Dryad Digital Repository. As you may recall, we ask all authors to agree to make data available; this is one way to achieve that. A full list of recommended repositories can be found on our website.

The following link will take you to the Dryad record for your article, so you won't have to re‐enter its bibliographic information, and can upload your files directly: 

http://datadryad.org/submit?journalID=pgenetics&manu=PGENETICS-D-21-00525R2

More information about depositing data in Dryad is available at http://www.datadryad.org/depositing. If you experience any difficulties in submitting your data, please contact help@datadryad.org for support.

Additionally, please be aware that our data availability policy requires that all numerical data underlying display items are included with the submission, and you will need to provide this before we can formally accept your manuscript, if not already present.

----------------------------------------------------

Press Queries

If you or your institution will be preparing press materials for this manuscript, or if you need to know your paper's publication date for media purposes, please inform the journal staff as soon as possible so that your submission can be scheduled accordingly. Your manuscript will remain under a strict press embargo until the publication date and time. This means an early version of your manuscript will not be published ahead of your final version. PLOS Genetics may also choose to issue a press release for your article. If there's anything the journal should know or you'd like more information, please get in touch via plosgenetics@plos.org.

Acceptance letter

Gregory P Copenhaver, Subba Reddy Palli

29 Jun 2021

PGENETICS-D-21-00525R2

CRISPR/Cas9 modified An. gambiae carrying kdr mutation L1014F functionally validate its contribution in insecticide resistance and combined effect with metabolic enzymes.

Dear Dr Grigoraki,

We are pleased to inform you that your manuscript entitled "CRISPR/Cas9 modified An. gambiae carrying kdr mutation L1014F functionally validate its contribution in insecticide resistance and combined effect with metabolic enzymes." has been formally accepted for publication in PLOS Genetics! Your manuscript is now with our production department and you will be notified of the publication date in due course.

The corresponding author will soon be receiving a typeset proof for review, to ensure errors have not been introduced during production. Please review the PDF proof of your manuscript carefully, as this is the last chance to correct any errors. Please note that major changes, or those which affect the scientific understanding of the work, will likely cause delays to the publication date of your manuscript.

Soon after your final files are uploaded, unless you have opted out or your manuscript is a front-matter piece, the early version of your manuscript will be published online. The date of the early version will be your article's publication date. The final article will be published to the same URL, and all versions of the paper will be accessible to readers.

Thank you again for supporting PLOS Genetics and open-access publishing. We are looking forward to publishing your work!

With kind regards,

Katalin Szabo

PLOS Genetics

On behalf of:

The PLOS Genetics Team

Carlyle House, Carlyle Road, Cambridge CB4 3DN | United Kingdom

plosgenetics@plos.org | +44 (0) 1223-442823

plosgenetics.org | Twitter: @PLOSGenetics

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    S1 Text. CRISPR/Cas9 strategy for generating Kisumu-F/F.

    Fig A: Strategy for the construction of the CRISPR/Cas9 donor plasmid. The nucleotide sequence of the central part (600bp) of the An. gambiae vgsc (Gene ID: AGAP004707) fragment (1,600bp in total) used to construct the CRISPR/Cas9 donor plasmid for HDR is depicted. Light orange areas correspond to exons 18 and 19. Position 2,422,652 (based on the AgamP3 reference sequence, chromosome arm 2L) where an A>T transversion generates the TTA―›TTT codon alteration creating mutation L1014F is marked with an asterisk. Underlined sequences correspond to the selected CRRISPR/Cas9 targets (gRNAs 1,2,3 and 4). Green areas mark the PAM (-NGG) triplets for each gRNA in the target sequence. Red letters show the SNPs introduced in the donor sequence. These include silent mutations in the gRNA target site to avoid cleavage of the donor plasmid from Cas9 and the A>T transversion creating mutation L1014F. Letters below red letters show the original sequence. Sequencing of the region in individuals from the Kisumu-F/F strain revealed that silent mutations introduced in the target sequences of gRNA’s 2,3 and 4 were retained while those of gRNA 1 were not. Fig B: Comparison of knock-down and mortality. The percentage of mosquitoes being knocked-down (immobile or unable to stand or take off) immediately after exposure to standard WHO assays (1h exposure time) was recorded, as well as the mortality 24h later based on standard WHO criteria (2). Error bars represent the SD (At least 3 replicates of 20, 2–5 day old female mosquitoes each were used per strain). Table A: Summary of screening G1 progeny to identify positive transformants. Table B: Primers used.

    (DOCX)

    S1 Data. Raw data for toxicity bioassays and fitness cost experiments.

    (XLSX)

    Attachment

    Submitted filename: Responses to reviewers.docx

    Attachment

    Submitted filename: Responses to reviewers.docx

    Data Availability Statement

    All relevant data are within the manuscript and its Supporting Information files.


    Articles from PLoS Genetics are provided here courtesy of PLOS

    RESOURCES